Compare Cisco Systems Inc (CSCO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs Sanofi SA — how do they compare? Cisco Systems Inc trades at $123.47 (market cap $474.67B), while Sanofi SA trades at $43.5 (market cap $104.30B). The key difference: Cisco Systems Inc is far larger — about 4.6× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| CSCO | SNY | |
|---|---|---|
Market Cap | $474.67B | $104.30B |
Volume | 22,887,319 | — |
Sector | Technology | Health |
52-Week High | $130.00 | $52.34 |
52-Week Low | $66.20 | $41.33 |
Enterprise Value | $489.33B | $124.19B |
Dividend Yield | 1.4% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $122.57, up 0.94% today, near its recent highs driven by strong AI cybersecurity momentum. The stock shows bullish technical signals with moving averages supporting the uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, CSCO reported revenue of $56.65B in 2025 with a net income margin of 19.69%, and has beaten EPS estimates for three consecutive quarters. Recent news highlights partnerships and product launches in AI security, fueling investor optimism.
CSCO's outlook is positive with a consensus price target of $133.25, implying ~9% upside, supported by 52% analyst buy ratings. Key opportunities include growth in AI-driven networking and security demand, but risks involve high valuation multiples (P/E 40.14) and competitive pressures in the tech sector. Investors should weigh strong cash flow generation against execution risks in a dynamic market.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
